|Awarded On||November 19, 2015|
|Title||The role of Prdm16 and histone H3 lysine 9 methyltransferase complex in MDS|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Daisuke Nakada|
We will address how a transcriptional regulator Prdm16 controls histone-modifying enzymes to aberrantly promote epigenetic silencing in myelodysplastic syndromes (MDS). MDS is a heterogeneous hematological disorder characterized by insufficient hematopoiesis, morphological dysplasia, and frequent progression into acute myeloid leukemia (AML). Since MDS is more prevalent in the elder patients, potentially curative therapies such as bone marrow transplant (BMT), which have high therapy-related mortality for elders, is not available. MDS occurs not only de novo but also as a consequence of chemo- or radiotherapies against other malignancies. Thus, understanding the pathogenesis of MDS has broad...